Literature DB >> 10700825

Comparison of proton therapy and conformal X-ray therapy in non-small cell lung cancer (NSCLC).

C H Lee1, D Tait, A E Nahum, S Webb.   

Abstract

This study compares the performance of one proton and four conformal X-ray planning techniques in treating non-small cell lung cancer (NSCLC). The treatment volumes for 13 NSCLC patients undergoing radical radiotherapy were planned using the five different techniques and dose-volume histograms (DVH) were used extensively in the comparative analysis. The minimum dose to the phase 2 target volume was escalated to 90 Gy, or until the point at which pre-set tolerance limits of spinal cord or lung were exceeded. The proton plan could treat nine of the 13 patients up to a dose of 90 Gy. Among the four X-ray techniques, performance varied enormously. One of them could not treat any of the patients, even to the conventional 60 Gy level, without failing to meet one or more of the criteria, whilst another one could treat 10 out of the 13 patients, although with this technique only four were permitted to have the dose escalated to 90 Gy. It was also found that two of the 13 patients could not be treated by any of the proton or X-ray plans to the conventional level, and were therefore considered unsuitable for radical radiotherapy. Various issues in conformal NSCLC radiotherapy including organ movement, tumour control, other possible organs at risk etc., are also discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10700825     DOI: 10.1259/bjr.72.863.10700825

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  6 in total

1.  Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer.

Authors:  Arya Amini; Katherine Ciura; James Welsh; Ngoc Nguyen; Matt Palmer; Pamela K Allen; Michael Paolini; Zhongxing Liao; Jaques Bluett; Radhe Mohan; Daniel Gomez; James D Cox; Ritsuko Komaki; Joe Y Chang
Journal:  Med Dosim       Date:  2013       Impact factor: 1.482

Review 2.  Do we have enough evidence to implement particle therapy as standard treatment in lung cancer? A systematic literature review.

Authors:  Madelon Pijls-Johannesma; Janneke P C Grutters; Frank Verhaegen; Philippe Lambin; Dirk De Ruysscher
Journal:  Oncologist       Date:  2010-01-12

3.  Clinical results of proton beam therapy for elderly patients with non-small cell lung cancer.

Authors:  Takashi Ono; Tatsuya Nakamura; Hisashi Yamaguchi; Yusuke Azami; Kanako Takayama; Motohisa Suzuki; Hitoshi Wada; Yasuhiro Kikuchi; Masao Murakami; Kenji Nemoto
Journal:  Radiat Oncol       Date:  2018-02-05       Impact factor: 3.481

4.  High Dose Hypofractionated Proton Beam Therapy is a Safe and Feasible Treatment for Central Lung Cancer.

Authors:  Takashi Ono; Tomonori Yabuuchi; Tatsuya Nakamura; Kanako Kimura; Yusuke Azami; Katsumi Hirose; Motohisa Suzuki; Hitoshi Wada; Yasuhiro Kikuchi; Kenji Nemoto
Journal:  Radiol Oncol       Date:  2017-06-16       Impact factor: 2.991

5.  Proton beam therapy is a safe and feasible treatment for patients with second primary lung cancer after lung resection.

Authors:  Takashi Ono; Tatsuya Nakamura; Yusuke Azami; Motohisa Suzuki; Hitoshi Wada; Yasuhiro Kikuchi; Masao Murakami; Kenji Nemoto
Journal:  Thorac Cancer       Date:  2018-12-26       Impact factor: 3.500

6.  The clinical results of proton beam therapy in patients with idiopathic pulmonary fibrosis: a single center experience.

Authors:  Takashi Ono; Masato Hareyama; Tatsuya Nakamura; Kanako Kimura; Yuichiro Hayashi; Yusuke Azami; Katsumi Hirose; Yoshiomi Hatayama; Motohisa Suzuki; Hitoshi Wada; Yasuhiro Kikuchi; Kenji Nemoto
Journal:  Radiat Oncol       Date:  2016-04-18       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.